Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-01-18
2005-01-18
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S247100, C424S197110, C424S198100
Reexamination Certificate
active
06843998
ABSTRACT:
Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.
REFERENCES:
patent: 5919665 (1999-07-01), Williams et al.
patent: 9100725 (1991-01-01), None
patent: WO 9532738 (1995-12-01), None
patent: WO 9633273 (1996-10-01), None
patent: WO 9807864 (1998-02-01), None
Tani et al, “Effect of a New Cholecystokinin Receptor Antagonist Loxiglumide on Acute Pancreatitis in Two Experimental Animal Models”, Pancreas 5: pp. 284-290 (1990).
Rizo et al, “Mechanics of membrane fusion”, Nature Structural Biology 5: pp. 839-842 (Oct. 1998).
Niemann et al, “Clostridial neurotoxins: new tools for dissecting exocytosis”, Trends in Cell Biology 4: pp. 179-185(May 1994).
Coffield et al, “The Site and Mechanism of Action of Botulinum Neurotoxin in Therapy with Botulinum Toxin”, Neurological Disease and Therapy, Therapy with Botulinum Toxin, pp. 3-13 (1994).
Tonello et al, “Tetanus and Botulism Neurotoxins in Intracellular Protein Catabolism”, Adv. Exp. Med. Biol. 389, pp. 251-260 (1996).
Sharma et al, “Hemagglutinin Binding Mediated Protection of Botulinum Neurotoxin From Proteolysis”, Journal of Natural Toxins 7: pp. 239-253(1998).
Kennedy et al, Identification of Two Amino Acids of the Human Cholecystokin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin, The Journal of Biological Chemistry, 272: pp. 2920-2926 (1997).
Pohl et al, “Ligand-induced Internalization of Cholecystokinin Receptors”, The Journal of Biological Chemistry 272: pp. 18179-18184 (1997).
Ji et al, “Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling”, The Journal of Biological Chemistry 272, pp. 24393-24401 (1997).
Jagerschmidt et al, “Mutation of Asp100in the Second Transmembrane Domain of the Cholecystokinin B Receptor Increases Antagonist Binding and Reduces Signal Transduction”,Molecular Pharmacology 48: pp. 783-789(1995).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain, Biochemistry” 34: pp. 15175-15181 (1995).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A*”, The Journal of Biologcal Chemistry, pp. 14721-14729 (1992).
Oblatt-Montal et al, “Formation of ions channels in lipid bilayers by a peptide with predicted transmembrane sequence of botulinum neurotoxin A”, Protein Science, vol. 4: pp. 1490-1497(1995).
Ulrich et al, “Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor”, Gen Bank 416772, Web site ncbi.nlm.nih.gov.
Binz et al, “The complete sequence of the botulinum type A neurotoxin and its comparison with other Clostridial neurotoxins”, Gen Bank M30196, Web Site ncbi.nlm.nih.gov.
Sharma et al, “Functional role of Hn-33; Enhanced cleavage of synaptic protein SNAP-25 b botulinum neurotoxin A and E”, Database Chemabs ‘Online’, XP-002154380 (Abstract)Book of Abstracts, 216thACS National Meeting, Boston, Aug. 23-27 (1998).
Fujita-Yoshigaki et al, “Vesicle-associated membrane protein 2 is essential for cAMP-regulated exocytosis in rat parotid acinar cells. The inhibition of cAMP-dependent amylase release by botulinum neurotoxin B”, XP-002154378(Abstract) J. Biol. Chem. (1996), 271(22) 13130-13134.
Aoki Kei Roger
Sachs George
Steward Lance E.
Allergan Inc.
Fisher Carlos A.
Nolan Patrick J.
Stathakis Dean G.
Voet Martin A.
LandOfFree
Methods and compositions for the treatment of pancreatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of pancreatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of pancreatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375601